FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)

{"title":"FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)","authors":"Alexander Spira , Byoung Chul Cho , Enriqueta Felip , Edward B. Garon , Koichi Goto , Melissa Johnson , Natasha Leighl , Antonio Passaro , David Planchard , Sanjay Popat , James Chih-Hsin Yang , Xiaoqian Lu , Yong Jiang , Jack Huang , Morgan Lam , Marcin Kowanetz , Shirley Wang , John Le , Jerry Y. Hsu , Cai-Cun Zhou","doi":"10.1016/j.lungcan.2024.108066","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"199 ","pages":"Article 108066"},"PeriodicalIF":4.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169500224006007","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}